The cell and gene therapy (CAGT) research and development space continues to expand rapidly with emerging biopharmas (EBPs) taking the lead in developing advanced therapies (ATs). In the Japan-Asia Pacific (JAPAC) region, AT development is robust and holds great potential. However, conducting CAGT trials for new therapies comes with its own unique operational complexities, including but not limited to: site selection and start-up, regulatory pathways and logistics. In this white paper, we examine the different strategies for EBPs in managing complex CAGT clinical trials and enhancing the probability of regulatory and clinical success within the EBP's capabilities and resources. 

Download our white paper to learn how EBPs can overcome the challenges in operating complex CAGT clinical trials, including engaging an experienced and flexible outsourcing partner with a vast network to provide comprehensive and tailored solutions, enabling EBPs to successfully navigate the growing AT development space.

To learn more about IQVIA APAC's CAGT solutions, please click here.